Linac-based stereotactic
radiotherapy has little effect on the majority of advanced
neoplasms. Therefore, the novel radiosensitizer Kochi
oxydol-
radiation therapy for unresectable
carcinomas (KORTUC) II, which contains
hydrogen peroxide and
sodium hyaluronate, was developed. The effectiveness of KORTUC II for the treatment of
chemotherapy-resistant supraclavicular
lymph node metastases, recurrent
breast cancer and stage IV primary
breast cancer has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II for patients with stage I primary
breast cancer. A total of 15 patients (age range, 40-76 years) were enrolled. The injection of 3 ml of KORTUC II agent was initiated from the sixth
radiotherapy fraction and was performed twice a week, under ultrasonographic guidance. The
therapeutic effects were evaluated by PET-CT and/or MRI examinations prior to and following KORTUC II treatment. All patients exhibited complete responses and the overall survival rate was 100% after a follow-up period of five years. The mean duration of follow-up at the end of March 2015 was 53 months. Based on these results, KORTUC II treatment exhibited marked
therapeutic effects with satisfactory treatment outcomes and an acceptable extent of adverse events.